INTRODUCTION
In the healthy intestine, regulatory mechanisms limit T-cell responsiveness to the commensal microbiota and environmental antigens in order to maintain homeostasis, but dysregulation of these mechanisms can lead to pathological inflammation and development of inflammatory bowel disease (IBD). Accordingly, intestinal T-cells remain one of the main targets for IBD therapy, 1 but the endogenous factors that regulate T-cell activity in the human gut are not fully understood.
The balance of T-cell regulatory and effector functions are determined partly during priming in gut-associated lymphoid tissue or mesenteric lymph nodes. Signals derived from the activating dendritic cell and local environment can influence the differentiation of naive CD4 þ T-cells toward a variety of effector or regulatory fates. However, it is now clear that T-cell properties are not fixed during priming but instead these cells retain functional plasticity and their function can be modified by signals encountered later upon homing to the intestinal mucosa. [2] [3] [4] Type 1 interferon (IFN-1), predominantly IFNa and IFNb, has emerged as a potent context/timing-dependent modifier of T-cell function. 5 IFN-1 binds to the IFN-1 receptor (IFNAR) and can differentially activate members of the signal transduction and transcription (STAT) family to determine downstream cytokine production. 6 For example, in murine T-cells IFN-1 signaling via STAT1 inhibits IFNg production, whereas signaling via STAT4 instead promotes IFNg. 7 IFN-1 limits viral replication in acute infection, but can also contribute to viral persistence in chronic infection models via the induction of IL-10 producing CD4 þ T-cells. This suggests a potential role for IFN-1 in chronic T-cell-driven inflammatory disorders. [8] [9] [10] In mice, constitutive low-level production of IFNb occurs in several tissues even in the absence of viral infection. 11 This suggests that, at least in mice, endogenous IFN-1 may regulate T-cell expression of STAT proteins and control responsiveness to subsequent stimuli. 6 In murine models, IFNAR deficiency increases susceptibility to dextran sodium sulfate colitis, 12 whereas administration of IFN-1 can ameliorate dextran sodium sulfate colitis via a mechanism that depends on TLR9/bacterial DNA. 13, 14 However, reports that local delivery of IFN-1 by a transgenic Lactobacillus acidophilus led to increased severity of dextran sodium sulfate colitis 12 underscore the complex role of IFN-1 in maintaining mucosal integrity.
In a T-cell transfer model of colitis, IFN-1 signaling induced by poly(I:C) can ameliorate gut inflammation via a mechanism thought to require both FoxP3 þ regulatory T-cells 15, 16 and IFNAR expression by the grafted colitogenic T-cells. 17 In human multiple sclerosis, therapeutic administration of IFN-1 promotes T-reg IL-10 expression while restricting IL-17-driven inflammation. 18 While genome-wide association studies have detected IFNAR variants associated with increased risk for developing IBD, 19 IFN-1 therapy displayed only limited efficacy in human IBD. 20 Given that constitutive expression and function of IFN-1 in human intestinal immunity is not known, we aimed to determine how IFN-1 influences signaling pathways at single-cell resolution in defined populations of intestinal T-cells in health and IBD.
RESULTS

IFN-1 is constitutively expressed in human colon and modulates the function of intestinal T-cells
To assess whether IFN-1 influences T-cell function in the human intestine, we first sought evidence that T-cells are responsive to IFN-1 in human colon. To do this, we assessed mRNA expression levels of interferon-stimulated genes (ISGs; myxovirus resistance A-MxA and 2 0 -5 0 oligoadenylate synthetase-2 0 5 0 OAS) in cells migrated out of human colonic biopsy tissue during overnight incubation in the presence or absence of IFN-1. The intestinal T-cells were then isolated by fluorescence-activated cell sorting (FACS) and subjected to quantitative reverse transcriptase-PCR. Alternatively, cells were obtained without IFN-1, but then exposed or not to brief (15 min) IFN-1 stimulation, and then permeabilized for assessment of pSTAT1 expression. Both approaches revealed that IFN-1 treatment of either healthy colon or IBD tissue increased intestinal T-cell expression of MxA (median 30-fold, Figure 1a ) and 2'5'OAS (median 50-fold, Figure 1b) , and induced an B10-fold increase in the frequency of CD4 þ T-cells expressing pSTAT1 (Figure 1d , representative FACS plots Figure 1c) .
We next sought to identify direct evidence of IFN-1 in the human colon, focusing on the IFNb isoform thought to coordinate many key effects of IFN-1. 6 Technical challenges have hampered previous attempts to directly detect IFN-1 in human tissues, but a recent publication successfully observed IFNb expression in human skin using immunohistochemistry analysis of freshly frozen clinical samples. 21 We therefore used a similar immunohistochemistry approach to visualize endogenous IFNb in colonic tissue. IFNb was detected, We next sought evidence that human intestinal T-cells can be influenced by IFN-1 exposure in situ. We detected pSTAT1 in both naïve and memory subsets of CD4 þ T-cells both before and after IFN-1 stimulation, but the frequency of pSTAT1 þ cells was significantly higher in the stimulated memory cell population (see Supplementary Figure S2 ). Accordingly, expression of the T-cell activation marker CD69 was detected only among CD45RA À memory cells, and the CD69 þ population included a higher frequency of pSTAT1 þ cells, suggesting increased responsiveness to IFN-1 specifically in the activated memory T-cell compartment (see Supplementary Figure S3 ). Since these cells exhibited low-level ''constitutive'' phosphorylation of STAT1 and expression of ISGs even in the absence of IFN-1 supplementation (Figure 1a-d) , we next assessed whether exposure to endogenous IFN-1 during the cell isolation process was sufficient to induce STAT1 signaling. To do this, we established walk-out cultures in the presence or absence of neutralizing anti-IFNb antibody and assessed T-cell expression of total STAT1 and pSTAT1. As phosphorylation is a brief process and the neutralization was conducted over the 24-h walk-out period, it was felt more likely to detect an effect in total STAT1 expression, which is known to be influenced by IFN-1 signaling. 6 Neutralization of IFNb significantly reduced the frequency of U-STAT1 þ CD4 þ T-cells detected (Figure 2a and b) , suggesting that constitutively produced IFNb was biologically active in these cultures. Additionally, these cells had reduced responsiveness to further IFN-1 stimulation with decreased frequency of pSTAT1 þ cells (Figure 2c, d ). This is consistent with endogenous IFNb priming CD4 þ T-cells in their responsiveness to IFN-1. In contrast, addition of neutralizing anti-IFNg did not significantly alter STAT1 phosphorylation or total STAT1 levels (data not shown). Collectively these data support a role for IFNb produced constitutively within human intestinal tissue as a potential modulator of gut T-cell function, signaling at least in part via STAT1 activation.
Phosphorylation of STAT1 and IFNb responsiveness are enhanced in intestinal CD4 þ T-cells from IBD patients
In order to assess whether IFN-1:STAT1 signaling is altered in human IBD, we next compared CD4 þ T-cell responsiveness with IFNb and pSTAT1 expression between IBD patients and control donors. To do this, we focused our analyses on cells isolated from macroscopically and histologically non-inflamed areas of colon in order to exclude signaling signatures associated with active inflammation. Even in unstimulated tissue cultures, we observed marked expression of pSTAT1 among CD4 þ T-cells isolated from the intestinal mucosa (Figure 1c, d) , although the total frequency of pSTAT1 þ cells was significantly higher in colonic tissue from IBD patients (Figure 1d ). Upon supplementation with exogenous IFN-1, both IBD colon samples and control tissues exhibited B10-fold increases in the proportion of derivative cells containing pSTAT1 (Figure 1d) . Similar data were obtained in parallel analysis of samples of inflamed mucosal tissue from IBD patients, although the total proportion of pSTAT1 þ cells detected was lower (see Supplementary Figure S4 ). These data indicated that under both resting and inflammatory conditions, CD4 þ T-cells in IBD colon exhibit increased STAT1 activation compared with their counterparts in control tissue samples. We therefore proceeded to investigate whether the increased levels of pSTAT1 detected in CD4 þ T-cells in IBD tissue could indicate enhanced Th1 polarization, as described in an earlier report. 22 However, our analyses revealed that pSTAT1 was expressed at comparable levels in both Tbet þ (Th1 cells) and Tbet À subsets of gut CD4 þ T-cells (Figure 3a-c) , indicating that pSTAT1 was not a surrogate marker of Th1 cells in this setting.
Collectively these data demonstrated that STAT1 phosphorylation and putative IFN-1 signaling were modulated in T-cells that migrated out of IBD colon, irrespective of whether the tissue was overtly inflamed. Conceptually, these effects could reflect intrinsic T-cell properties, exposure to soluble factors released by the cultured tissue, or a combination of these effects. To test for the presence of IBD-associated factors that might initiate STAT1 phosphorylation, we assessed the ability of IBD tissue culture supernatants to induce pSTAT1 in CD4 þ T-cells derived from control colon tissue. Despite extensive investigation, we found no consistent evidence that soluble factors released from IBD tissue could upregulate pSTAT1 in healthy colonic CD4 þ T-cells (data not shown). These findings indicated that IBD-associated changes in STAT1 phosphorylation and responsiveness to IFN-1 were at least in part due to intrinsic properties of the T-cells. Accordingly, we observed that gut T-cells from IBD patients exhibited greater IFN-1-induced ISG expression (Figure 3d, e) . Furthermore, we detected a strong trend toward reduced expression of the STAT1 regulator SOCS1 (suppressor of cytokine signaling 1) in intestinal T-cells freshly isolated from IBD patients (Figure 3f) . Taken together, these data indicate that altered IFN-1 responsiveness and STAT1 phosphorylation in IBD are at least in part due to changes in gut T-cell-intrinsic properties.
IFNb:STAT1 signaling exerts differential effects on T-cell function in healthy tissue and IBD colon When we assessed the ability of IFN-1 to activate alternative STAT family members in intestinal CD4 þ T-cells, we observed marked phosphorylation of both STAT3 (twofold increase) and STAT5 (fourfold increase) in response to IFN-1 exposure, but we did not detect any differences between patients and controls either at baseline or in the cytokinetreated cultures (Figure 4a ). These data suggested that differential effects of IFNb on STAT activation in T-cells from IBD patients were specific to STAT1. We therefore proceeded to investigate whether the increased IFN-1 responsiveness and STAT1 phosphorylation observed in IBD patient T-cells was restricted to the gut or reflected system-wide changes in T-cell function. To do this, we analyzed CD4 þ T-cells in peripheral blood and observed that the trace numbers of pSTAT1 þ cells were significantly increased by IFN-1 stimulation, particularly within the CD45RA À memory/effector compartment (32.1% ± 22 pSTAT1 þ post stimulation) in CD45RA À cells vs. 18.2% ± 15.2 in CD45RA þ cells, Po0.05 ANOVA). However, we observed no significant difference in IFNb responsiveness between IBD patients and controls even when comparing gut-homing CD4 þ T-cells (b7 integrin þ ) with CD4 þ T-cells targeted to other sites (b7-negative; Figure 4b ). These data indicated that IBD-associated changes in IFN-1 responsiveness and pSTAT1 expression of intestinal CD4 þ T-cells are local effects that do not reflect systemic alterations in these patients.
There is increasing evidence from murine models that constitutive IFNb expression can support regulatory T-cell responses, 15, 16 but the function of this cytokine in the human intestine is currently unknown. To address this question, we obtained T-cells from colonic biopsy tissue cultured in the presence or absence of neutralizing anti-IFNb antibody and measured cytokine production and expression of master regulator transcription factors upon re-stimulation with anti-CD3 and anti-CD28. Addition of anti-IFNb to the biopsy cultures did not alter T-cell expression of the transcription factors T-bet or FoxP3 as assessed by intracellular staining (Figure 5a, b) , and RORgt expression was very low throughout (data not shown). Nonetheless, intracellular cytokine staining of cells isolated from healthy tissue revealed that anti-IFNb treatment induced a significant decrease in the frequency of CD4 þ T-cells producing IL-10 ( Figure 5c) , with a trend towards an increased frequency of IFNg-producing cells (Figure 5d ), accompanied by a significant increase in supernatant concentration of IFNg detected by enzyme-linked immunosorbent assay (ELISA) (Figure 6b) . Tumor necrosis factor-a and IL-17A production were also observed, although IFNb neutralization failed to alter the amount detected either by intracellular staining (Figures 5e, f) or by ELISA measurement (Figures 6c, d) . These findings suggest a potentially important role for endogenous IFNb in modulating the balance of IFNg and IL-10 production by local T-cells in healthy tissues to favor the expression of anti-inflammatory cytokines. This effect is likely due to functional modulation by environmental signals rather than altered T-cell differentiation fates, since the transcription factor profiles observed were not altered by IFN-1 exposure.
These ''pro-regulatory'' effects of IFNb treatment in control tissues were absent when we repeated these experiments using colon samples from IBD patients, even though the tissues 
analyzed were obtained from non-inflamed regions of the intestine (macroscopically and histologically normal; Figures 5  and 6 ). In IBD biopsy organ culture, treatment with neutralizing anti-IFNb induced an increase in the proportion of intestinal T-cells producing IFNg, tumor necrosis factora , and IL-17A, and trend towards increased production of IL-10 ( Figure 5a ), accompanied by a significant increase in supernatant IL-10 levels as assessed by ELISA (Figure 6a) .
Consistent with previous reports, T-cells expressing T-bet or
Foxp3 were more frequent in IBD tissue than in control samples (see Supplementary Figure S5) , 23, 24 but as observed in healthy tissue expression of these transcriptional regulators was not altered by neutralization of IFNb (figures 5a, b) . Therefore, endogenous IFNb has a pro-regulatory effect in healthy tissue, where this cytokine promotes IL-10 production, whereas in IBD our data indicate that IFNb instead restricts a number of effector T-cells producing cytokines in the intestine.
DISCUSSION
This study reports that endogenous IFNb promotes STAT1 phosphorylation in human intestinal T-cells to exert proregulatory effects in the healthy gut. We also present evidence that this axis is disrupted in IBD, where endogenous IFNb instead restricts effector T-cell cytokine responses, even when assessing macroscopically and histologically non-inflamed areas of the gut.
We observed that T-cells isolated from human intestinal tissue were responsive to IFN-1 in vitro, as demonstrated by phosphorylation of multiple STAT signaling proteins and marked induction of ISG expression. The induction of ISG expression was on total (CD3 þ ) T-cells and the differential contribution of CD8 and CD4 populations cannot be determined. We also detected that a proportion of T-cells migrating out of cultured biopsy tissue expressed the phosphorylated form of STAT1, which is the primary family member involved in IFN-1 signaling. This finding suggested that gut T-cells may be exposed to IFNb cytokine in situ, and accordingly we observed for the first time that IFNb is present in human colonic tissue. It is unclear what the source of the IFN-1 is although the epithelium appears to be important and this would be an interesting area for further research. There is increasing evidence from murine models that constitutive production of IFN-1, and IFNb in particular, can exert immunoregulatory effects. 15, 16, 25 Consistent with this concept, neutralization of IFNb in biopsy cultures from healthy donors significantly reduced the generation of IL-10 þ T-cells, whereas the frequency of IFNg þ T-cells and quantity of IFNg detected in the culture supernatants were increased.
The differences between the intracellular staining of the intestinal T-cells compared with the ELISA data may be due to the contribution of other cell types in the supernatants and their differential response to IFNb. It is likely that other IFN-1 subtypes are also present in the environment and it is not possible to conclude about the functional importance of all IFN-1 in this system. However, the overall findings are consistent with data from the murine T-cell transfer model of colitis, in which IFN-1 was found to be critical for maintaining regulatory T-cell function. 15, 16 However, in contrast with the experimental models, our data did not demonstrate any effect of IFN-1 on expression of FoxP3, which is less tightly linked to regulatory function in the human system. 26 It has been suggested that the IFN-1 effects on T-cell function are context dependent. 27 Consistent with this concept, our data demonstrate that the effects of IFNb differ in healthy and IBD mucosa. Our findings are best explained by plasticity of intestinal T-cells and their responsiveness to local environmental signals. Our analysis provided no evidence for altered differentiation to major T-cell fates as defined by expression of master transcriptional regulators.
Phosphorylation of STAT1 in gut T-cells was demonstrated within 15 min of exposure to IFN-1, suggesting a direct effect of IFN-1 on T-cells, but it is not possible to exclude a contribution from other cell types in these cultures to many of the effects measured. The varied results obtained by ELISA analysis of supernatants from both control and IBD tissue cultures ( Figure 6 ) do suggest a differential role of IFN-1 on non-T-cells, although the small tissue samples available precluded further investigation of this issue. Indeed, an early study on the role of interferon on lamina propria mononuclear cells (LPMCs) suggested that, in regard to cytotoxicity, LPMCs from IBD patients can be relatively hyporesponsive to exogenous interferon. 28 Several of our observations indicate altered IFN-1 responsiveness and STAT1 phosphorylation of gut T-cells in IBD. For this analysis, we focused primarily on tissue sampled from macroscopically and histologically non-inflamed areas of intestine in order to identify underlying immunoregulatory changes that might otherwise be masked by ongoing inflammatory processes. The frequency of pSTAT1 þ CD4 þ T-cells detected was higher in non-inflamed IBD colon than in control tissue both in unstimulated cultures and after exposure to IFN-1 in vitro. This difference was specific for STAT1 in the intestinal mucosa, since we were unable to identify any modulation of alternative IFN-1-sensitive STATs or detect any changes in T-cells derived from the blood. Indeed, we were also unable to induce phosphorylation of STAT1 in control T-cells upon incubation with the culture supernatant of IBD biopsies, suggesting that enhanced pSTAT1 expression by IBD T-cells is an intrinsic property of these cells rather than being conferred by a soluble factor.
Previous studies have typically focused on analyzing STAT expression in whole samples of inflamed IBD tissue (containing numerous different cell types). Instead, we have for the first time used a novel phosflow-based method to measure the phosphorylated forms of STAT proteins at the single-cell level in distinct subsets of human leukocytes in the absence of overt mucosal inflammation. Using this approach, we observed an increased frequency of pSTAT1 þ intestinal CD4 þ T-cells in tissue from IBD patients, consistent with a previously shown trend for increased pSTAT1 levels in whole-tissue homogenates, and increases in total STAT1 protein identified in CD4 þ lamina propria cells. 29 However, we did not observe the previously reported increases in STAT3 expression and phosphorylation in IBD, 29, 30 which may reflect cell-type specific differences or could perhaps be attributed to our approach of analyzing non-inflamed tissue.
In addition to increased expression of pSTAT1, intestinal CD4 þ T-cells from non-inflamed IBD intestinal tissue were significantly more responsive to IFN-1 stimulation as assessed by induction of ISG expression. Given the direct relationship between exposure to IFN-1 and expression of this gene set, this observation again suggests direct effects of IFN-1 on the T-cell population. SOCS1 is a major regulator of STAT1 signaling in T-cells, and conditional KO of Socs1 in murine T-cells has been shown to exacerbate colitis. 31 SOCS1 is induced by IFN-1 and acts via numerous mechanisms as part of a negative feedback loop in IFN-1-STAT1 signaling. 32 In our study, there was a strong trend toward reduced SOCS1 expression in intestinal T-cells freshly isolated from non-inflamed IBD tissue; we observed a corresponding increase in total STAT1 levels in these cells. It is therefore likely that reduced SOCS1 control of STAT1 signaling contributes to increased IFN-1 sensitivity of gut T-cells in IBD. Consistent with this altered responsiveness to IFN-1, we further observed that neutralization of IFNb during IBD biopsy culture increased the frequency of derivative T-cells producing IFNg, tumor necrosis factor-a or IL-17A. These data suggest that the non-inflamed IBD mucosa represents a modified signaling environment in which endogenous IFNb acts to restrain production of pro-inflammatory cytokines rather than promoting IL-10 expression, perhaps to prevent the development of overt inflammation. We also detected a strong trend toward reduced ISG expression by gut T-cells when measured directly after isolation from IBD tissues compared with control tissue. Based on these observations, we propose that in IBD tissue the constituent T-cells exhibit altered responsiveness to endogenous IFNb and other subsequent environmental signals, which could in part explain the seemingly conflicting early data on the role these cytokines play in IBD.
While the efficacy of IFN-1 treatment in IBD has been largely disappointing, 20 there have been promising early results from a phase 1 trial of UC patients treated with the IFN-1-inducing TLR9 agonist DIMS0150. 33 More recently, it has been demonstrated that patients with either UC or Crohn's disease have a distinct ''virobiota'' compared with household controls, 34 suggesting that IFN-1 may be an important factor in the complex interactions between viruses, bacteria, and the host immune system during the pathogenesis of IBD.
In summary, this study demonstrates that human colon constitutively expresses IFNb, which has a selective STAT1-dependent pro-regulatory effect on cytokine production by intestinal T-cells. This finding is consistent with mouse models in which IFN-1 signaling via STAT1 inhibits IFNg production. 35 Our observations are also in agreement with the concept that the balance of STAT proteins and their activation determines the outcome of subsequent exposure to IFN-1 and other local triggers. Specifically, in this view IFN-1 maintains a basal repertoire STAT expression that forms a platform for specific T-cell responses. 6 This IFN-1-shaped level of T-cell responsiveness would be an important determinant of local immune responses against viruses and other pathogens in the human intestine while preventing an excessive inflammatory response.
METHODS
Patient samples and cell isolation. Intestinal tissues were collected from patients with IBD during endoscopy or surgery, and control tissues were collected from subjects who were undergoing follow-up because of rectal bleeding, altered bowel habits, or cancer. The diagnosis for each patient was made using clinical parameters, radiographic studies, and histological criteria. All tissue and blood donors gave informed written consent, and the study was approved by the local research ethics committee. Patient information is presented in Supplementary Information.
Cells were extracted from intestinal tissue by enzymatic digestion or ''walk-out'' culture as previously described. [36] [37] [38] Briefly, the tissue was treated with 1 mmol l À 1 dithiothreitol (Sigma-Aldrich, St Louis, MO) to remove faeces and mucus, followed by 1 mmol l À 1 EDTA (Sigma-Aldrich) in Hank's balanced salt solution (Sigma-Aldrich) to remove epithelium. Digestion was by 1 mg ml À 1 collagenase D (Roche Applied Science Penzberg, Upper Bavaria, Germany) in HEPESbuffered RPMI 1640 medium (Sigma-Aldrich) containing 2% fetal calf serum (PAA, Little Chalfont, UK) and 20 mg ml À 1 deoxyribonuclease I (Roche Applied Science). A lamina propria (LP) cell suspension was passed through a 40-mm cell strainer. Alternatively, biopsies were cultured for ''walk-out'' following EDTA processing. The denuded tissue was placed in 0.5 ml complete medium (RPMI1640 Dutch Modification supplemented with 2 M L-glutamine, 100 U ml À 1 penicillin, 100 mg ml À 1 streptomycin, 100 mg ml À 1 gentamicin (all SigmaAldrich) and 10% heat-treated (56 1C for 30 min) fetal calf serum (PAA). Cultures were established in 24-well plates (Becton Dickinson, Franklin Lakes, NJ) at one biopsy in 0.5 ml of medium per well and placed in a humidified incubator at 37 1C with 5% CO 2 in air. In some experiments the medium was supplemented with IFNb (Peprotech, Rocky Hill, NJ) at 1000 IU ml À 1 or with an equal volume of the diluent phosphate-buffer saline as a control. Alternatively, human anti-IFNb antibody or an isotype-matched mouse IgG1 control antibody (both from Biolegend, San Diego, CA) were added at 1 mg ml À 1 (Biolegend). The biopsies were then discarded after 48 h culture and egressed cells collected from the remaining medium by centrifugation at 400 g for 5 min. Typically, 80% of viable cells isolated from non-inflamed or control samples were CD3 þ , and 75% of these cells were CD4 þ . Viability was assessed using Live/Dead staining.
Peripheral blood mononuclear cells were obtained from healthy volunteer donors or patients by centrifugation over Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK) at 650 g for 20 min.
Antibody labeling and flow cytometry. Cells were incubated with monoclonal antibodies on ice for 15 min in 100 ml FACS buffer (phosphate-buffered saline with 2% v/v fetal calf serum, 1 mmol l À 1 EDTA and 0.2% sodium azide), washed by centrifugation, and fixed in 1% (wt/vol) paraformaldehyde. Cells were acquired on a FACSCanto II (BD Biosciences, Franklin Lakes, NJ), using CellQuest software (BD Biosciences) and analyzed using WinList 6.0 software (Verity, Topsham, ME). Positively stained cells were identified relative to isotype-matched control antibody staining. A full list of the monoclonal antibodies used is provided in Supplementary Materials.
Analysis of phosphorylated antigens by flow cytometry. A technique for measuring intracellular phosphorylated antigens in single cells was developed and optimized as part of this study. LPMCs isolated by walk-out were re-suspended in 100 ml complete medium with gentamicin in 5 ml FACS tubes and either left unstimulated or stimulated with 40,000 IU ml À 1 IFNa2A (Peprotech), for 15 min in a 37 1C water bath. The cells were then fixed by addition of an equal volume of 4% w/v paraformaldehyde for 10 min in a 37 1C water bath.
The fixed cells were washed by centrifugation in phosphate-buffer saline and then incubated in 1 ml of 70% cold methanol (VWR, Radnor, PA) on ice for 30 min for permeabilization. The cells were washed twice in FACS buffer and then re-suspended in 100 ml FACS buffer for simultaneous cell surface and intracellular antibody labeling. Cells were labeled as appropriate and incubated for 30-60 min at room temperature. After one further wash with FACS buffer the cells were re-suspended in 300 ml of FACS buffer and analyzed by flow cytometry as described.
Stimulation of T-cells for cytokine analysis. LPMCs were cultured in 200 ml complete medium in 96-well plates (Beckton Dickinson), and low endotoxin azide free anti-CD3 and anti-CD28 antibodies (Biolegend) were added each at a final concentration of 1 mg ml À 1 . The plates were put in a humidified incubator at 37 1C with 5% CO 2 in air for 20 h. After 20 h the cells were collected into 5 ml FACS tubes, and the Golgi-blocking agent monensin (VWR) was added at 3 mM final concentration and the tube contents mixed thoroughly. The FACS tubes were replaced in the incubator for 4 h. Cells were then collected and processed by flow cytometry after centrifugation and supernatants were stored at À 80 1C.
Isolation of intestinal or peripheral T-cells by flow sorting. LPMCs, collected by walk-out technique, were washed by addition of excess FACS buffer, centrifugation at 400 g for 5 min and discarding of supernatant. The cells were then resuspended into 100 ml filter sterilized (0.2 mm), modified FACS buffer (lacking sodium azide), and incubated with relevant monoclonal antibodies for 15 min on ice protected from light. Cell populations within LPCs were isolated by flow-sorting using a FACS Aria cytometer (Becton Dickinson). In order to sort only viable T-cells, the agent 7-amino-actinomycin D (Biolegend) was used in combination with CD3 þ labeling.
Quantitative real-time polymerase chain reaction. RNA extraction and reverse transcription were performed using the RNeasy Micro Kit and QuantiTect Reverse Transcription Kit, respectively. Quantitative real-time PCR was performed using the QuantiFast SYBR Green PCR Kit (all from Qiagen Venlo, Limburg, Netherlands) on a 7500 RealTime PCR System (Applied Biosystems, Foster City, CA). Full primers are listed in Supplementary Materials. Expression data were normalized to GAPDH using the 2 À DCt method.
Multiplex ELISA. Measurement of tumor necrosis factor-a, IL-10, IFNg, and IL-17A in culture supernatants was performed using the FlowCytomix Multiplex Kit (eBioscience, San Diego, CA) according to the manufacturer's instructions. Data were acquired on a Canto II Flow Cytometer (BD Bioscience), set up as recommended by the kit manufacturer and data analyzed using FlowCytomixPro (eBioscience) software.
Immunohistochemistry. Colonic biopsies were snap frozen in liquid nitrogen. Slides were prepared by the pathology service at the Royal London Hospital (Barts Health, London, UK). Slides were fixed with addition of 1 ml of paraformaldehyde 4%. 1 ml blocking serum (5% bovine serum albumin, 0.1% Tween in phosphate-buffer saline) was added followed by addition of primary antibodies. The antibodies used were as shown in Supplementary Materials. Secondary antibodies were applied: AF555 goat anti-mouse IgG (Invitrogen, Waltham, MA) and/or AF488 donkey anti-rabbit IgG (Invitrogen). Mounting medium was with DAPI (Vectashield, Vector Laboratories, Burlingame, CA). Analysis was performed with a Research Systems Microscope BX61 (Olympus, Tokyo, Japan), with digital image capture at Â 100 (standard) or Â 200 (high power) using the software system SmartCapture v3.0 (Digital Scientific, Cambridge, UK).
Statistics. Statistical analyses were performed using SigmaStat 3.5 (Systat Software, San Jose, CA). Comparisons between two groups of paired, normally and non-normally distributed data were analyzed using Paired t-test, Student's t-test and Signed rank test, respectively. Data sets of more than two groups were compared by analysis of variance with pairwise comparisons by Holm-Sidak test. Po0.05 was regarded as statistically significant.
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